Aktuellt
SENASTE
Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development as it improves the company's financial position. Under the agreement, Xbrane will receive an upfront payment of USD10m, along with potential milestone payments of USD3m and double-digit royalties on future sales. The partner, Intas Pharmaceuticals, will finance and manage the clinical and regulatory development of Xdivane.
LÄS MER
